2026 Volume 41 Issue 2 Pages 160-166
Topical antibiotic therapy is an effective treatment option for bacterial otitis media and otitis externa because it enables the direct delivery of high drug concentrations to the site of infection. This approach can be regarded as an efficient drug delivery system that maximizes local antimicrobial exposure while minimizing systemic adverse effects. Traditionally, fluoroquinolone ear drops (such as ofloxacin) have been widely used for these indications. However, the recent increasing prevalence of antimicrobial resistance and need to improve clinical efficacy have highlighted the limitations of conventional formulations. Based on pharmacokinetic/pharmacodynamic (PK/PD) principles, a high-concentration levofloxacin formulation, ComlexⓇ Otic solution 1.5%, was developed to address these challenges. Levofloxacin, the optically active S-enantiomer of ofloxacin, exhibits superior antibacterial activity, and its high local concentration is designed to achieve optimal PK/PD targets at the infection site. This strategy is expected to enhance the bactericidal activity and reduce the likelihood of resistance development by ensuring sufficient drug exposure above the minimum inhibitory concentration. ComlexⓇ Otic solution 1.5% has been formulated with careful consideration of safety. Notably, it does not contain preservatives, reducing the risk of local irritation and has a low potential for ototoxicity, making it suitable for use even in cases where the integrity of the tympanic membrane may be compromised. These characteristics contribute to its favorable safety profile and support its use in routine clinical practice. In context of the global increase in antimicrobial-resistant pathogens, appropriate use of potent topical antibiotics for the initial treatment of ear infections is increasingly important. When used as first-line therapy, ComlexⓇ Otic solution 1.5% has the potential to improve the reliability of treatment outcomes, promote rapid resolution of infection, and contribute to the suppression of antimicrobial resistance. Consequently, this high-concentration levofloxacin formulation represents a promising therapeutic option for the effective management of bacterial otitis media and otitis externa.
